An At-Home Nasal Vaccine
These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.
MM&M9h
AstraZeneca: New drug data, promising earnings and a $3.5B R&D investment
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
2minutemedicine.com29d
AstraZeneca’s FluMist first and only self-administered flu vaccine
FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...
Nature1d
Fresh from the biologic pipeline—2009
In September, AstraZeneca's subsidiary MedImmune gained approval for a live H1N1 Flumist vaccine. Further afield, Beijing-based Sinovac Biotech also received approval for an H1N1 vaccine from the ...
EuropaWire27d
AstraZeneca Presents New Data at IDWeek 2024, Showcasing Progress in Respiratory Disease Prevention and Vaccine Innovation
AstraZeneca reaffirmed its commitment to combating infectious ... In addition, vaccine effectiveness data on FluMist, the only self-administered flu vaccine approved in the US, will be presented. Real ...
American Association of Individual Investors2d
Which Is a Better Investment, AstraZeneca plc (ADR) or Novartis AG (ADR) Stock?
AstraZeneca PLC, a biopharmaceutical company ... Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare ...